NCT03112096View on ClinicalTrials.gov

A Phase I [18F]THK-5351 Positron Emission Tomography Study in Healthy Subjects and Alzheimer's Disease

PHASE1CompletedINTERVENTIONAL

Enrollment

12

Participants

Timeline

Start Date

May 17, 2017

Primary Completion Date

August 31, 2018

Study Completion Date

August 31, 2018

Conditions

Alzheimer Disease

Interventions

DRUG

[18F]THK-5351

Imaging for evaluating the biodistribution, pharmacokinetics and safety of abnormal tau protein in the brain

Trial Locations (1)

05505

Asan Medical Center, Seoul

Sponsors

Lead Sponsor

Asan Foundation

All Listed Sponsors

lead

Asan Foundation

OTHER